Transit-time flowmetry (TTFM) allows grafts quality control during coronary artery bypass surgery by measuring the flow volume through them.
To date, many studies have deeply studied the predictive role on the graft outcomes of the various flowmetry-derived parameters. One of the least investigated aspects, however, is the mutual influence that two newly realized grafts can have. This possibility would be related to the presence of a more or less developed collateral circulation between the bypassed territories.
The purpose of this study is to assess whether a graft for a territory different than that provided by the left anterior descending artery (LAD) may affect the functionality (measured through flowmetry) of the left internal mammary artery - LAD graft.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* age \> 18 years;
* informed consent acquired and registered;
* patients who undergo coronary artery bypass grafting (with or without cardiopulmonary bypass);
* patients with stable angina, unstable angina or acute coronary syndrome without elevation of the ST tract (NSTEMI)
Exclusion Criteria:
* patients unable to give informed consent;
* patients undergoing emergency surgery;
* patients in unstable haemodynamic conditions or in need of pharmacological or mechanical support;
* patients undergoing combined surgery;
* patients undergoing single aortocoronary bypass surgery
Primary outcome measure(s)
LIMA>LAD Pulsatility index (PI) modification — During the surgery, out of cardiopulmonary bypass The primary aim of this study is to assess whether a graft for a non-LAD coronary target modifies the performance (measured by flowmetry) of the flow in the LIMA\>LAD graft.
PI is expressed by the ratio of the flow volume amplitude and mean flow volume, both quantified by a flowmeter (ml/min / ml/min). An ideal value would be \< 3
Trial sites (1)
Facility
City
Region
Status
Fondazione Policlinico Gemelli IRCCS
Roma
Italy
More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
